Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Clinical benefits of the talazoparib and enzalutamide combination extend to patients with both BRCA and non-BRCA homologous recombination repair gene alterations.

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...

Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...

Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...

HRR mutations are commonly of germline origin, with several real world studies suggesting a 23-44% probability of an HRR alteration to be of germline origin: 1 The following summarizes recommendations ...

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive ...

Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ...

Rapid Review Quiz: Prostate Cancer Are you up-to-date on the latest research into prostate cancer and how it might affect your patients? Test yourself with a short quiz. Medscape, October 26, 2023 ...